“Grail also fell sharply in the first quarter, noting that its top-line data from its cancer screening test failed to meet its endpoint of detecting more cancer in stages 1 and 2. While the study...”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.